You are currently browsing the archives for the life science funding category.
Bio-Rad has sponsored the development of
this site to advance the productivity of the American Biotechnology sector and the fine people who
work in it across the country. We invite readers to contribute content:
posters, tools, research and presentations, articles white papers, multimedia, music
downloads and entertainment, conference announcements, videos. Please contact firstname.lastname@example.org more information.
Download the Protein Blotting Guide
Download the Stem Cell Guide for Life Science Researchers
:: Posted by American Biotechnologist on 04-30-2013
Yesterday morning (April 29, 2013), President Obama addressed the National Academy of Sciences on the occasion of the academy’s 150th anniversary. While any organization has the right to celebrate 150 years of existence, this particular anniversary has been darkened by the dark cloud of sequestration and looming funding cuts to our country’s research and development programs.
During his speech, Obama promised that he was committed to investing in science, however, he hinted that the funding should come from private investment, since the sequester is expected to shave close to $1.5 Billion dollars off of the all-important NIH budget. Such cuts pose a real threat to scientific progress and Obama mentioned that
Instead of racing ahead … our scientists are left wondering if they’ll be able to start any new research projects at all, which means we could lose a year, two years, of scientific research.
Scary stuff. Are you worried about your research? How do you think sequestration will affect your research?
:: Posted by American Biotechnologist on 03-16-2012
Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease.
Calibr will be led by Peter G. Schultz, Ph.D., a world-renowned chemist and biotechnology entrepreneur. The Institute will offer academic scientists, around the world, a streamlined, efficient and flexible path for translating their biomedical research into novel medicines.
:: Posted by American Biotechnologist on 03-06-2012
Proteomics is about to take a big leap forward, that is if the NIH can help it.
Last week, the NIH put out a request for information aimed at determining how best to accelerate research in disruptive proteomics technologies. The organization is hoping that submissions will aim to greatly outperform current mass spec technologies and introduce an all new way of advancing proteomic questions.
According to the proposal:
The Disruptive Proteomics Technologies (DPT) Working Group of the NIH Common Fund wishes to identify gaps and opportunities in current technologies and methodologies related to proteome-wide measurements. For the purposes of this RFI, “disruptive” is defined as very rapid, very significant gains, similar to the “disruptive” technology development that occurred in DNA sequencing technology.
These are exciting times for the field of proteomics. Don’t be left behind! Click here to find out more on how to get involved today!